Dostęp otwarty
Subskrybcja albo opłata za dostęp do treści numeru/artykułu
Rola immunomodulatorów w leczeniu choroby Leśniowskiego-Crohna w dobie terapii biologicznych
DOI: https://doi.org/10.26625/gp.2017.9.2.30
Abstrakt
Słowa kluczowe
Pełny tekst:
Bibliografia
Rieder F., Reinisch W.: Thiopurines and the natural course of Crohn’s disease: did we finally find the right therapeutic target? Am J Gastroenterol 2014, 109, 1037-1040.
Magro F., Rodrigues-Pinto E., Coelho R. i wsp.: Is it possible to change phenotype progression in Crohn’s disease in the era of immunomodulators? Predictive factors of phenotype progression. Am J Gastroenterol 2014, 109, 1026-1036.
Chhaya V., Pollok R.C.G., Cecil E. i wsp.: Impact of early thiopurines on surgery in 2770 children and young people diagnosed with inflammatory bowel disease: a national population-based study. Aliment Pharmacol Ther 2015, 42, 990-999.
Cosnes J., Bourrier A., Laharie D. i wsp.: Early administration of azathioprine versus conventional management of Crohn’s disease: a randomized controlled trial. Gastroenterology 2013, 145, 758-765.
Panes J., Lopez-Sanroman A., Bermejo F. i wsp.: Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn’s disease. Gastroenterology 2013, 145, 766-774.
Chande N., Tsoulis D.J., MacDonald J.K.: Azathioprine or 6-mercaptopurine for induction of remission in Crohn’s disease. Cochrane Database Syst Rev 2013, 4, CD000545.
Chande N., Townsend C.M., Parker C.E. i wsp.: Azathioprine or 6-mercaptopurine for induction of remission in Crohn’s disease (Review). Cochrane Database of Syst Rev 2016, 10, CD000545.
Sandborn W.J., Sutherland L.R., Pearson D. i wsp.: Azathioprine or 6-mercaptopurine for induction of remission in Crohn’s disease (Review). Cochrane Database Syst Rev 2009, 4, CD000545.
Dassopoulos T., Sultan S., Falck-Ytter Y.T. i wsp.: American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn’s disease. Gastroenterology 2013, 145, 1464-1478.
Gomollón F., Dignass A., Annese V. i wsp.: 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management. JCC 2017, 3-25.
Present D.H., Korelitz B.I., Wisch N. i wsp.: Treatment of Crohn’s disease with 6-mercaptopurine. N Engl J Med 1980, 302, 981-987.
Punati J., Markowitz J., Lerer T. i wsp.: Effect of early immunomodulator use in moderate to severe pediatric Crohn disease. Inflamm Bowel Dis 2008, 14, 949-954.
Qiu Y., Chen B.L., Mao R. i wsp.: Endoscopy assessment at 1-year identifies long-term responders to thiopurines maintenance therapy in patients with Crohn’s disease. Medicine (Baltimore) 2015, 94, e1204.
Ardizzone S., Bollani S., Manzionna G. i wsp.: Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn’s disease: a randomized, investigator-blind study. Dig Liver Dis 2003, 35, 619-627.
Mate-Jimenez J., Hermida C., Cantero-Perona J. i wsp.: 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid dependent inflammatory bowel disease. Eur J Gastroenterol Hepatol 2000, 12, 1227-1233.
Colombel J.F., Sandborn W.J., Reinisch W. i wsp.: Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 2010, 362, 1383-1395.
D’Haens G., Baert F., van Assche G. i wsp.: Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet 2008, 371, 660-667.
Van de Casteele N., Gils A., Singh S. i wsp.: Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol 2013, 108, 962-971.
Hanauer S.B., Wagner C.L., Bala M. i wsp.: Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease. Clin Gastroenterol Hepatol 2004, 2, 542-553.
Hazlewood G.S., Rezaie A., Borman M. i wsp.: Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn’s disease: a network meta-analysis. Gastroenterology 2015, 148, 344-354.
McDonald J.W.D., Wang Y., Tsoulis D.J. i wsp.: Methotrexate for induction of remission in refractory Crohn’s disease. Cochrane Database Syst Rev 2014, 8, CD003459.
Sunseri W., Hyams J.S., Lerer T. i wsp.: Retrospective cohort study of methotrexate use in the treatment of pediatric
Crohn’s disease. Inflamm Bowel Dis 2014, 20, 1341-1345.
Oren R., Moshkowitz M., Odes S. i wsp.: Methotrexate in chronic active Crohn’s disease: a double-blind, randomized, Israeli multicenter trial. Am J Gastroenterol 1997, 92, 2203-2209.
Arora S., Katkov W., Cooley J. i wsp.: Methotrexate in Crohn’s disease: results of a randomized, double-blind, placebo-controlled trial. Hepatogastroenterology 1999, 46, 1724-1729.
Feagan B.G., Fedorak R.N., Irvine E.J. i wsp.: A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. N Engl J Med 2000, 342, 1627-1632.
Khan K.J., Dubinsky M.C., Ford A.C. i wsp.: Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2011, 106, 630-642.
Schröder O., Blumenstein I., Stein J.: Combining infliximab with methotrexate for the induction and maintenance
of remission in refractory Crohn’s disease: a controlled pilot study. Eur J Gastroenterol Hepatol 2006, 18, 11-16.
Vermeire S., Noman M., Van Assche G. i wsp.: Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease. Gut 2007, 56, 1226-1231.
Feagan B.G., McDonald J.W., Panaccione R. i wsp.: Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn’s disease. Gastroenterology 2014, 146, 681-688.
Terdiman J.P., Gruss C.B., Heidelbaugh J.J. i wsp. and the AGA Institute Clinical Practice and Quality Management Committee. American Gastroenterological Association Institute Guideline on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn’s disease. Gastroenterology 2013, 145, 1459-1463.
Bouhnik Y., Lémann M., Mary J.Y. i wsp.: Long-term follow up of patients with Crohn’s disease treated with azathioprine or 6-mercaptopurine. Lancet 1996, 347, 215-219.
Holtmann M., Krummenaeur F., Claas C. i wsp.: Long-term effectiveness of azathioprine in IBD beyond 4 years: a European multicenter study in 1176 patients. Dig Dis Sci 2006, 51, 1516-1524.
Wenzl H.H., Primas C., Novacek G. i wsp.: Withdrawal of long-term maintenance treatment with azathioprine tends to increase relapse risk in patients with Crohn’s disease. Dig Dis Sci 2015, 60, 1414-1423.
Vilien M., Dahlerup J.F., Munck L.K. i wsp.: Randomized controlled azathioprine withdrawal after more than two years treatment in Crohn’s disease: increased relapse rate the following year. Aliment Pharmacol Ther 2004, 19, 1147-1152.
Sokol H., Seksik P., Nion-Larmurier I. i wsp.: Current smoking, not duration of remission, delays Crohn’s disease
relapse following azathioprine withdrawal. Inflamm Bowel Dis 2010, 16, 362-363.
Van Assche G., Magdelaine-Beuzelin C., D’Haens G. i wsp.: Withdrawal of immunosuppression in Crohn’s disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008, 134, 1861-1868.
Schnitzler F., Fidder H., Ferrante M. i wsp.: Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a singlecentre cohort. Gut 2009, 58, 492-500.
Lichtenstein G.R., Feagan B.G., Cohen R.D. i wsp.: Serious infection and mortality in patients with Crohn’s disease: more than 5 years of follow-up in the TREAT registry. Am J Gastroenterol 2012, 107, 1409-1422.
Beaugerie L., Brousse N., Bouvier A.M. i wsp.: Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009, 374, 1617-1625.
Kotlyar D.S., Osterman M.T., Diamond R.H. i wsp.: A systematic review of factors that contribute to hepatosplenic T-cell
lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2011, 9, 36-41.
Affronti A., Orlando A., Cottone M.: An update on medical management on Crohn’s disease. Expert Opin Pharmacother 2015, 16, 63-78.
Patel V., Wang Y., MacDonald J.K. i wsp.: Methotrexate for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev 2014, 8, CD006884.
Hausmann J., Zabel K., Herrmann E. i wsp.: Methotrexate for maintenance of remission in chronic active Crohn’s disease: long-term single-center experience and meta-analysis of observational studies. Inflamm Bowel Dis 2010, 16, 1195-1202.
Seinen M.L., Ponsioen C.Y., de Boer N.K. i wsp.: Sustained clinical benefit and tolerability of methotrexate monotherapy after thiopurine therapy in patients with Crohn’s disease. Clin Gastroenterol Hepatol 2013, 11, 667-672.
Suares N.C., Hamlin P.J., Greer D.P. i wsp.: Efficacy and tolerability of methotrexate therapy for refractory Crohn’s disease: a large single-centre experience. Aliment Pharmacol Ther 2012, 35, 284-291.
Schwartz D.A., Loftus E.V., Tremaine W.J. i wsp.: The natural history of fistulizing Crohn’s disease in Olmsted County, Minnesota. Gastroenterology 2002, 122, 875-880.
Tang L.Y., Rawsthorne P., Bernstein C.N.: Are perineal and luminal fistulas associated in Crohn’s disease? A population-based study. Clin Gastroenterol Hepatol 2006, 4, 1130-1134.
Gionchetti P., Dignass A., Danese S. i wsp.: 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 2: Surgical Management and Special Situations. J Crohn’s Colitis, 2017, 135-149.
Korelitz B.I., Present D.H.: Favorable effect of 6-mercatopurine on fistulae of Crohn’s disease. Dig Dis Sci 1985, 30, 58-64.
Sohn N., Korelitz B.I.: Local operative treatment of anorectal Crohn’s disease. J Clin Gastroenterol 1982, 4, 395-398.
Cosnes J., Bourrier A., Lahare D. i wsp.: Early administration of azathioprine vs. conventional management of Crohn’s disease: A randomized controlled trial. Gastroenterology 2013, 145, 758-765.
Pearson D.C., May G.R., Fick G.H. i wsp.: Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 1995, 123, 132-142.
de la Poza G., Lopez-Sanroman A., Taxonera C. i wsp.: Genital fistulas in female Crohn’s disease patients. Clinical
characteristics and response to therapy. J Crohn’s Colitis 2012, 6, 276-280.
Peyrin-Biroulet L., Deltenre P., Ardizzone S. i wsp.: Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn’s disease: a meta-analysis. Am J Gastroenterol 2009, 104, 2089-2096.
D’Haens G.R., Vermeire S., van Assche G. i wsp.: Therapy of metronidazole with azathioprine to prevent postoperative
recurrence of Crohn’s disease: a controlled randomized trial. Gastroenterology 2008, 135, 1123-1129.
Gordon M., Taylor K., Akobeng A.K. i wsp.: Azathioprine and 6-mercaptopurine for maintenance of surgically-induced
remission in Crohn’s disease. Cochrane Database Syst Rev 2014, 8, CD010233.
Savarino E., Bodini G., Dulbecco P. i wsp.: Adalimumab is more effective than azathioprine and mesalamine
at preventing postoperative recurrence of Crohn’s disease: a randomized controlled trial. Am J Gastroenterol 2013, 108 (11), 1731-1742.
De Cruz P., Kamm M.A., Hamilton A.L. i wsp.: Efficacy of thiopurines and adalimumab in preventing Crohn’s disease recurrence in high-risk patients – a POCER study analysis. Aliment Pharmacol Ther 2015, 42 (7), 867-879.
Ng S.W., Mahadevan U.: My treatment approach to management of the pregnant patient with inflammatory bowel disease. Mayo Clin Proc 2014, 89, 355-360.
Sands K., Jansen R., Zaslau S. i wsp.: Review article: the safety of therapeutic drugs in male inflammatory bowel disease patients wishing to conceive. Aliment Pharmacol Ther 2015, 41, 821-834.
Tavernier N., Fumery M., Peyrin-Biroulet L. i wsp.: Systematic review: fertility in non-surgically treated inflammatory bowel disease. Aliment Pharmacol Ther 2013, 38, 847-853.
Norgard B., Pedersen L., Jacobsen J. i wsp.: The risk of congenital abnormalities in children fathered by men treated with azathioprine or mercaptopurine before conception. Aliment Pharmacol Ther 2004, 19, 679-685.
Rajapakse R.O., Korelitz B.I., Zlatanic J. i wsp.: Outcome of pregnancies when fathers are treated with 6-mercaptopurine
for inflammatory bowel disease. Am J Gastroenterol 2000, 95, 684-688.
Akbari M., Shah S., Velayos F. i wsp.: Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. Inflamm Bowel Dis 2013, 19, 15-22.
Teruel C., Lopez-San Roman A., Bermejo F. i wsp.: Outcomes of pregnancies fathered by inflammatory bowel disease patients exposed to thiopurines. Am J Gastroenterol 2010, 105, 2003-2008.
Feagins L.A., Kane S.V.: Sexual and reproductive issues for men with inflammatory bowel disease. Am J Gastroenterol
, 104, 768-773.
Weber-Schoendorfer C., Hoeltzenbein M., Wacker E. i wsp.: No evidence for an increased risk of adverse pregnancy outcome after paternal low-dose methotrexate: an observational cohort study. Rheumatology 2014, 53, 757-763.
Mahadevan U., Loftus Jr E.V., Tremaine W.J. i wsp.: Azathioprine or 6-mercaptopurine before colectomy for ulcerative colitis is not associated with increased postoperative complications. Inflamm Bowel Dis 2002, 8, 311-316.
Subramanian V., Saxena S., Kang J.Y. i wsp.: Preoperative steroid use and risk of postoperative complications in patients with inflammatory bowel disease undergoing abdominal surgery. Am J Gastroenterol 2008, 103, 2373-2381.
Katz S., Pardi D.S.: Inflammatory bowel disease of the elderly: frequently asked questions (FAQs). Am J Gastroenterol 2011, 106, 1889-1897.
Ansari A., Patel N., Sanderson J. i wsp.: Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with infl ammatory bowel disease. Aliment Pharmacol Ther 2010, 31, 640-647.
Vazquez S.R., Rondina M.T., Pendleton R.C.: Azathioprine-induced warfarin resistance. Ann Pharmacother 2008, 42, 1118-1123.
Greenwald D.A., Brandt L.J.: Infl ammatory bowel disease aft er age 60. Curr Treat Options Gastroenterol 2003, 6, 213-225.
Beaugerie L., Brousse N., Bouvier A.M. i wsp.: Lymphoproliferative disorders inpatients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009, 374, 1617-1625.
Kotlyar D.S., Lewis J.D., Beaugerie L. i wsp.: Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clin Gastroenterol Hepatol 2015, 13, 847-858.
Taleban S., Elquzac E., Gower-Rousseau C.: Cancer and inflammatory bowel disease in the elderly. Dig Liv Dis 48, (2016), 1105-1111.
Singh S., Nagpal S.J., Murad M.H. i wsp.: Inflammatory bowel disease is associatedwith an increased risk of melanoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2014, 12, 210-218.
Long M.D., Martin C.F., Pipkin C.A. i wsp.: Risk of melanoma and nonmelanoma skincancer among patients with inflammatory bowel disease. Gastroenterology 2012, 143, 390-399.
Peyrin-Biroulet L., Khosrotehrani K., Carrat F. i wsp.: Increased risk for non-melanoma skin cancers in patients who receive thiopurines for inflammatorybowel disease. Gastroenterology 2011, 141, 1621-1628.
Pedersen N., Duricova D., Elkjaer M. i wsp.: Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis
of population-based cohort studies. Am J Gastroenterol 2010, 105, 1480-1487.
Pasternak B., Svanstrom H., Schmiegelow K. i wsp.: Use of azathioprine and the riskof cancer in inflammatory bowel disease. Am J Epidemiol 2013, 177, 1296-1305.
Bourrier A., Carrat F., Colombel J.F. i wsp.: Excess risk of urinary tract cancersin patients receiving thiopurines
for inflammatory bowel disease: a prospec-tive observational cohort study. Aliment Pharmacol Ther 2016, 43, 252-261.
Statystyki
Abstrakt - 599 PDF - 0Altmetric
Zewnętrzne odnośniki
- Obecnie brak jakichkolwiek odnośników.